Therefore, the mechanisms underlying acquired resistance to ALK inhibitors must be elucidated to develop novel strategies to treat patients with ALK-p advanced NSCLC, especially those with CNS metastases [4,12]. This evidence concerns the gene ALK and non-small cell lung carcinoma.